The Impact of Vitamin D in the Treatment of Essential Hypertension

Christian Legarth 1, Daniela Grimm 1,*; Markus Wehland 2, Johann Bauer 3 and Marcus Krüger 2

1 Institute of Biomedicine, Pharmacology, Aarhus University, Wilhelm Meyers Allé 4, DK-8000 Aarhus C, Denmark; chr_brod@hotmail.com
2 Clinic for Plastic, Aesthetic and Hand Surgery, Otto von Guericke University, Leipziger Str. 44, 39120 Magdeburg, Germany; markus.wehland@med.ovgu.de (M.W.); markus.krueger@med.ovgu.de (M.K.)
3 Max Planck Institute for Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany; jbauer@biochem.mpg.de
* Correspondence: dgg@biomed.au.dk; Tel.: +45-871-67693

Received: 12 January 2018; Accepted: 31 January 2018; Published: 3 February 2018

Abstract: The aim of this review is to investigate, whether there is a possible link between vitamin D supplementation and the reduction of blood pressure in hypertensive patients. The renin-angiotensin-aldosterone system is known for being deeply involved in cardiovascular tonus and blood pressure regulation. Hence, many of the pharmaceutical antihypertensive drugs inhibit this system. Interestingly, experimental studies in mice have indicated that vitamin D supplementation significantly lowers renin synthesis and blood pressure. It is conceivable that similar mechanisms may be found in the human organism. Regarding this, large-scale cross-sectional studies suggest the serum 25(OH)D-level to be inversely correlated to the prevalence of hypertension. However, randomized controlled trials (RCTs) have not found a clear association between vitamin D supplementation and improvements in hypertension. Nevertheless, the missing association of vitamin D and hypertension in clinical trials can be due to suboptimal study designs. There are hints that restoration of serum 25(OH)D levels during vitamin D therapy is essential to achieve possible beneficial cardiovascular effects. It is important to perform long-term trials with a short dose interval and a high bioavailability of supplementation. Taken together, more RCTs are required to further investigate if vitamin D can be beneficial for the reduction of blood pressure.

Keywords: vitamin D; hypertension; essential hypertension; renin-angiotensin-aldosterone system (RAAS); cholecalciferol

1. Introduction

According to the World Health Organization (WHO), one in three adults worldwide has raised blood pressure—a condition that causes around half of all deaths from stroke and heart disease [1]. Adiposity, lack of physical activity and excessive salt intake are some of the best-known environmental factors associated with hypertension. In recent years, yet another cause has been postulated: vitamin D deficiency [2–6]. Vitamin D is a key player in calcium homeostasis, in maintaining optimal bone metabolism and reducing fracture risk [7]. Several studies indicate that vitamin D also seems to play a protective role against the development of hypertension [5,8]. In this review, we summarize the existing literature that is concerned with vitamin D and hypertension and investigate if vitamin D (supplements) could be a beneficial treatment agent for hypertensive individuals.

For the literature search, the online databases PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), Scopus (http://www.scopus.com/) and clinicaltrials.gov (http://clinicaltrials.gov/) were used up to January 2018. Search terms such as; “(Cholecalciferol OR vitamin D) and hypertension”; “Essential hypertension and (cholecalciferol OR ergocalciferol)”; “Vitamin D deficiency and hypertension”, have
been applied in the online databases. There were no restrictions in language set up. In PubMed, a search for “Essential hypertension” gave 30986 items, “Vitamin D” 74983 items and “hypertension and vitamin D” gave 1950 items accessed on 29 January 2018.

2. Arterial Hypertension

2.1. Definition, Causes and Risks

Arterial hypertension belongs to the most prevalent diseases and accounts for about 7.5 million deaths per year (about 13% of all deaths) worldwide. According to the WHO, hypertension is a major risk factor for the development of a variety of diseases, including cardiovascular diseases (CVD), kidney failure, cognitive impairment etc. [1]. It is estimated that approximately 22% (about 1 billion individuals) of the adult population above 25 years of age worldwide suffer from arterial hypertension [1]. In Europe, hypertension affects about 30–45% of people as reported in 2013 [9]; a large proportion is still unaware of their condition and left untreated [10].

Hypertension is a condition, in which either the systolic blood pressure (SBP) and/or diastolic blood pressure (DBP) stays elevated persistently. An exact definition has been difficult to establish. However, in 2017 the American College of Cardiology has newly defined hypertension in the Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults [11]. The new classification is given in Table 1.

Table 1. Classification of hypertension.

| Classification            | SBP (mmHg) | DBP (mmHg) |
|---------------------------|------------|------------|
| Normal                    | <120       | <80        |
| Elevated                  | 120–129    | <80        |
| Hypertension, Stage 1     | 130–139    | 80–89      |
| Hypertension, Stage 2     | ≥140       | ≥90        |

Approximately 95% of all cases of arterial hypertension can be classified as essential hypertension (EH). This condition is characterized by an imbalance between vascular tonus and cardiac output without any identifiable cause.

The mean arterial BP (MAP) can be derived analogously from Ohm’s law [12], which states:

\[
\text{MAP} = \text{Cardiac Output (CO)} \times \text{Total Peripheral Resistance (TPR)}
\]

An increase in MAP can lead to small artery remodelling, which increases the media-to-lumen ratio, TPR, causes wall damage and reduces distensibility in large arteries. These alterations finally lead to vessel wall hypertrophy and further elevate SBP—a vicious circle is created [13].

Age, smoking, high Body Mass Index (BMI), a salty diet and genetic dispositions are some of the known environmental and hereditary precursors linked to EH. Hence, it is important to eliminate the triggers, increase level of physical exercise and normalize BMI. The importance of preventing hypertension is underpinned by the findings of Lewington et al. [14]. They found that a 2 mmHg lowering of normal SBP could give an approximately 10% reduced risk of stroke mortality [14].

2.2. Management of Hypertension

In addition to lifestyle changes, pharmaceutical treatment may be relevant. Thiazide diuretics where the first group of effective antihypertensive drugs to be introduced in 1958 [15]. Since then, many medications have been developed. The treatment goals are to reduce the number of CVD-events and thereby to improve mortality. Different drug classes are currently available for the treatment of hypertension: 1. Diuretics (thiazides) [16]. Some of the most extensively used drugs in this class include bendroflumethiazide, hydrochlorothiazide and indapamide [17]; 2. Calcium channel blockers:
Dihydropyridines such as amlodipine and nifedipine have specific impact on the vessels and induce a compensatory activation of baroreceptors [18]; 3. β-adrenoceptor antagonists: Metoprolol and atenolol with selectivity to β₁-adrenoceptors and propranolol with no selectivity are some of the most common drugs of this class [19]; 4. Blockers of the renin-angiotensin-aldosterone system (RAAS): The group of angiotensin-converting-enzyme inhibitors (ACEI) includes drugs such as enalapril and captopril [20], angiotensin II receptor blockers (ARBs) include losartan, azilsartan and valsartan [21], and 5. Direct renin inhibitors comprise drugs like aliskiren [22].

3. Vitamin D

Vitamin D contains a steroid scaffold and possesses lipophilic properties. About 80–90% is endogenously synthesized and the remaining 10–20% come from nutritional intake. The metabolic pathways of vitamin D are shown in Figure 1. The inactive vitamin D is found in two distinct forms in the organism, cholecalciferol (D₃) and ergocalciferol (D₂) respectively. These inactive forms must undergo two hydroxylations to become the active form 1,25(OH)₂D₃. The endogenous synthesis of cholecalciferol is catalysed by sun-exposure of the skin with UVB radiation. In this process, 7-dehydrocholesterol is transformed to pre-vitamin D₃, which isomerises to cholecalciferol. In the blood stream these two prohormones (D₃ and D₂) are bound to vitamin D binding protein (DBP). A hydroxylase enzyme in the liver, CYP2R1 (known as cytochrome P450 2R1), is responsible for converting D₂ and D₃ into 25(OH)D. The final activating step mainly takes place in the in proximal tubule cells, were 1α-hydroxylase (CYP27B1) converts 25(OH)D into 1,25(OH)₂D₃ named calcitriol. The last conversion step is highly regulated by feedback mechanisms [23].

![Figure 1. Overview of the vitamin D metabolism. 25(OH)D, Calcidiol; 1,25(OH)₂D₃, Calcitriol; CYP2R1, cytochrome P450 2R1; DBP, Vitamin D binding protein. Parts of the figure were drawn by using pictures from Servier Medical Art.](image)

3.1. The Vitamin D Receptor (VDR)

Brumbaugh et al. were the first to find evidence for the presence of a vitamin D receptor (VDR) [24]. This VDR is an intracellular receptor, able to bind 1,25(OH)₂D₃ and subsequently stimulate VDR to heterodimerize with retinoid X receptor (RXR) [23]. The VDR-RXR complex may translocate to the nucleus and bind to the regulatory site in the promoter region of DNA sequence elements. Thus, the gene expression of specific target genes will be regulated and facilitate synthesis of vitamin D-regulated
proteins. The well-known biological effects of 1,25(OH)₂D₃ include absorption of Ca²⁺ from the small intestine, bone metabolism and calcium- and phosphorus homeostasis (Figure 1). The global function of the vitamin D system becomes clear, when we take a look at the VDR distribution in various tissues and cells of the human body (Figure 2) [25].

![Figure 2. Tissue distribution of the Vitamin D receptor. Parts of the figure were drawn by using pictures from Servier Medical Art.](image)

3.2. Vitamin D Status

The lipophilic nature of the vitamin D₃ and the high binding affinity of 1,25(OH)₂D₃ to DBP in serum make these two substances difficult to use as markers. Thus, 25(OH)D concentration in plasma is considered the best measurement for vitamin D status [26].

Table 2 shows recommended doses of vitamin D intake and ideal serum 25(OH)D levels. However, there is an ongoing debate about the optimal levels of vitamin D. Intake reference values for vitamin D were developed by the Food and Nutrition Board (FNB) at the Institute of Medicine of The National Academies, USA. The Institute recommends 600 international units (IU) (15 µg) of vitamin D a day for adults ages 19 to 70. For adults age >70, the recommendation increases to 800 IU (20 µg) a day.

| Recommendation                                | Children and Adolescents | Adults          |
|-----------------------------------------------|--------------------------|-----------------|
| The optimal concentration of 25(OH)D in plasma | 20–60 ng/mL              | 30–80 ng/mL     |
| Supplementations: recommended dose when severe deficiency | ≈ 50–150 nM             | ≈ 75–200 nM     |
|                                               | up to 5000 IU/day = 125 µg/d | up to 7000 IU/day ≈ 175 µg/d |

Adverse effects of vitamin D supplementation are rare. The initial signs of vitamin D intoxication are hypercalcemia, hypercalciuria and hyperphosphatemia [27]. In case of an overdose, hypercalcemia and/or hyperphosphatemia-associated symptoms can occur. Examples are weakness, fatigue, headache, appetite loss, dry mouth, nausea, vomiting, cardiovascular symptoms and others.
3.3. Suppression of Renin Production

In 2002, Li et al. designed an in vivo study of renin expression in VDR-null mice [28]. One group of wildtype mice (n = 9) were compared with a group of VDR-null mice (n = 8). The mice were given optimal growing conditions. After two months of age, they were put on a special diet for five weeks to normalize the calcium levels in plasma. Afterwards, the BP was measured under anaesthesia, renin-expression as well as the angiotensin (ANG) II activity were analysed. Interestingly, these analyses revealed a significantly higher (>20 mmHg) diastolic BP and SBP in VDR-null mice vs. wildtype mice. To obtain quantitative values of mRNA renin-expression, the Northern blot method was used. A significant 3.5-fold higher renin-expression and 2.5-fold higher serum level of ANG II in VDR-null mice vs. wildtype mice was seen (p < 0.001) [28].

To investigate the direct effects of active vitamin D on renin synthesis, another group of wildtype mice had five injections of 30 pmol 1,25(OH)₂D₃ in three following days. It turned out that the 1,25(OH)₂D₃ treatment gave a 50% reduction in renin-mRNA, when compared to the control group (n ≥ 3 in each group). Taken together, these findings imply the importance of vitamin D as an effective suppressor of the renin synthesis.

To elucidate the molecular pathways behind the downregulating effect of vitamin D on renin-transcription, Yuan et al. prepared an in vitro study [29]. In this study, specific juxtaglomerular As4.1 tumour cells from mice kidneys were analysed. In As4.1 cells the cyclic adenosine monophosphate (cAMP) pathway (shown in Figure 3) is deeply involved in the transcription of prorenin-mRNA. A Gα₃-coupled protein activates adenylate cyclase (AC), which converts adenosine triphosphate (ATP) into cAMP. The elevated level of cAMP activates protein kinase A (PKA). The catalytic subunit of PKA then translocates to the nucleus, where it phosphorylates the cAMP response element-binding protein (CREB). Subsequently, CREB binds to its response element (CRE) in the promoter region of the Ren1C gene. The other co-activators CBP and p300 are recruited to form a CREB-CBP-CRE complex that promotes the gene transcription of pro-renin-mRNA.

Remarkably, 1,25(OH)₂D₃ liganded-VDR can interact directly with CREB to blunt its binding to CRE. It seems that these actions are carried out without the heterodimerization of liganded-VDR to RXR. Hence, it is believed that higher plasma levels of vitamin D can suppress the renin formation.

Figure 3. cAMP-PKA pathway. (a) Signalling in a juxtaglomerular cell in absence of 1,25(OH)₂-vitamin D₃; (b) Signalling in presence of 1,25(OH)₂-vitamin D₃. cAMP: cyclic adenosine monophosphate, CBP: CREB-binding protein, CRE: cAMP-dependent response element, CREB: cAMP response element-binding protein, Gα₃: Gα₃-protein alpha subunit, P: phosphate, PKA: protein kinase A, Pol II: RNA polymerase II, VDR: vitamin D receptor. The “+” stands for “JG in presence of”.
in juxtaglomerular cells [29]. However, another study indicates that decreased levels of renin in VDR-knockout mice will not cause a fall in BP [30]. Hence, it is important to state that more mechanisms must be implicated in a potential BP reducing effect of vitamin D.

4. Effects of Vitamin D on the Local Renin-Angiotensin System (RAS)

A local RAS is situated in several tissues, including heart, vessels, kidneys, lung, adrenal gland and nervous system [31]. The RAS acts in the control of cardiovascular, renal, and adrenal functions that regulate BP, body fluid and electrolyte status. It is known that the cardiac RAS is activated in cardiac pressure-overload and hypertensive rat models [32–35], and that the RAS plays an autocrine-paracrine role in the development of cardiac hypertrophy. VDR-deficient mice develop hypertension accompanied by an increase in heart weight. This finding reflects, at least in part, effects from activation of the systemic RAS [31].

Vitamin D is involved in cardiovascular protection, but only few studies examined the impact of the VDR in atherosclerosis. Macrophages express all components of the RAS, and are therefore involved in the process of atherosclerosis. It has been shown that macrophages in atherosclerotic lesions contain ANG II [36]. Another study showed that macrophage VDR signalling, in part by suppressing the local RAS, inhibits atherosclerosis in mice [37].

The antiatherosclerotic role of the VDR signalling in leukocytes/macrophages, and at least part of the antiatherosclerotic mechanism is to block the activation of the local RAS in macrophages and within the atherosclerotic lesion. Therefore, further studies to investigate the benefits of vitamin D and its analogues in atherosclerosis in both preclinical and clinical studies are desirable.

The intrarenal RAS is a key player for renal damage. Vitamin D deficiency activates the local RAS in the kidney, and thus it causes renal injury [38]. It is known that vitamin D is a negative RAS regulator by suppressing renin expression [28]. Moreover, vitamin D deficiency promotes the RAS [28], and a chronic RAS activation impacts lung function and induces a lung fibrosis [39]. Shi et al. showed in a recent paper that Vitamin D deficiency can induce profibrotic factors and activate the fibrotic cascade. These RAS-mediated effects are independent of an increased blood pressure [40]. In addition, there exists a local RAS in bone, which is involved in bone metabolism [41]. A recent study demonstrated that 1,25(OH)_2D_3 influences bone metabolism by downregulating the local bone RAS in a mice model with glucocorticoid-induced osteoporosis [42]. Vitamin D influences also the local pancreatic islet RAS and improves the islet beta cell secretory function [43]. A mice animal model with vitamin D receptor ablation revealed an activation of the islet RAS [43]. The application of calcitriol showed beneficial effects on the RAS activation under high-glucose conditions. In addition, it revealed a positive calcitriol effect on elevating the islet beta cell secretory response to glucose [43].

These animal studies show that vitamin D deficiency is a key player in different diseases. It influences the local RAS in various tissues. Vitamin D deficiency is an important health problem. Therefore, it is necessary to perform future studies to establish clinical guidelines for vitamin D supplementation required to achieve adequate vitamin D levels in people who are at risk for hypertension, atherosclerosis, cardiovascular disease, diabetes, pulmonary fibrosis, osteoporosis and others.

In particular, vitamin D deficiency might be linked to cardiovascular disease. There is a higher risk of high blood pressure (hypertension). However, more studies in this field are necessary. It is still too early to confirm and there is an ongoing discussion, whether a low vitamin D level causes hypertension or whether vitamin D supplementation will play a role in the treatment of hypertension. The role of vitamin D supplementation in the management or treatment of these diseases mentioned above must be studied in the future.

5. Vitamin D and Essential Hypertension

National Health and Nutrition Examination Survey (NHANES) is a survey providing information about health statistics in a representative sample of the U.S. population [44]. Based on the NHANES III
data (survey period 1988–1994), Martins et al. examine the association between serum 25(OH)D-level and the prevalence of hypertension [45]. In this cross-sectional study, all individuals with available data and above 20 years of age \( (n = 15,088) \) are included. The study population is then divided into quartiles according to their serum 25(OH)-level. The 1st Quartile (25(OH)D < 21 ng/mL) shows a 20.46% prevalence of hypertension, while the 4th Quartile (25(OH)D \( \geq \) 37 ng/mL) has a prevalence of 15.10%. Comparing the 1st to the 4th Quartile gives an odds ratio (OR) = 1.30 (95%CI: 1.13–1.48), adjusted for race, sex and age.

Scragg et al. use the same NHANES III data [46]. Here, individuals receiving anti-hypertensive medication are excluded and data is adjusted for physical activity, BMI, age, sex and race \( (n = 12,644) \). Both studies find a significant inverse correlation between BP and serum 25(OH)D level \( (p < 0.01) \). Ke et al. prepared a systematic review of the available observational studies in the period 2007–2014. It only includes published studies with healthy adults \( (n = 90,535) \) [2]. Comparing odds of hypertension from the top category to the bottom category of serum 25(OH)D level gives OR = 0.79 (95%CI: 0.73–0.87). This supports the hypothesis of an inverse relationship between hypertension and vitamin D status.

The strength of these studies is in particular due to the great sample size and it can be considered representative for the population. The disadvantages include the lack of temporal separation between data collection of exposure (vitamin D status) and outcome (hypertension). Hence, a causal relation can be difficult to establish even though a significant association is found. Furthermore, it can be hard to exclude the possibility of an inverse causality between exposure and outcome.

To meet the challenges of possible inverse causality between serum 25(OH)D level and hypertension, Kunutskor et al. reviewed all prospective studies in this field up until 2012 [47]. The included studies had to be representative for the population, with at least one year of follow-up and without prevalent hypertension at baseline \( (n = 283,537) \). Participants had serum 25(OH)D measured at baseline \( (n = 48,633) \) or vitamin D status assessed from dietary intake \( (n = 238,199) \). Hypertension during follow-up time was considered the endpoint.

Pooled relative risk (RR) in this review showed RR = 0.88 (95%CI: 0.81–0.97) i.e., a 12% reduction in risk of incident hypertension for every increase of 10 ng/mL in serum 25(OH)D level [47]. The group of participants with their vitamin D status based only upon the dietary intake had RR = 1.0 (95%CI: 0.95–1.05). Thus, no association between dietary vitamin D intake and risk of incident hypertension appeared. It is worth noting that dietary intake is a source of only 5–20% of vitamin D and its metabolites in plasma [48]. Therefore, it can be difficult to use the dietary intake as marker of vitamin D status, which can explain the lack of inverse correlation in this group.

To examine whether vitamin D supplementation is beneficial in hypertensive patients, the relevant studies are listed in Table 3. The included studies must meet the following criteria, to be discussed in review: participants should be adults (aged \( \geq 18 \) years) with diagnosed vitamin D deficiency and/or arterial hypertension at baseline. Identified studies must be published or last updated in the time period 1 January 2012 until 27 November 2017. The intervention group must be administered cholecalciferol and participants may not suffer from preeclampsia. To minimize confounding, only RCT will be assessed.
Table 3. Overview of recent clinical trials with vitamin D intervention in hypertensive patients.

| Title                                                                 | Design                                      | Objective                                                                                     | Conclusions                                                                                     |
|-----------------------------------------------------------------------|----------------------------------------------|------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| The Styrian Vitamin D Hypertension Trial: effects of vitamin D        | Randomized, Double-blind, Placebo-controlled,  | To assess the effects on 24-h systolic BP and diastolic BP of vitamin D₃ supplementation of 2800 IU/day for 8 weeks in vitamin D deficient individuals. | There was no significant effect on systolic and diastolic BP after treatment with vitamin D supplementation. |
| on blood pressure and cardiovascular risk factors. [49]               | n = 200                                      |                                                                                               |                                                                                                |
| Vitamin D therapy in individuals with prehypertension or hypertension: | Randomized, Double-blind, Parallel assignment, | To compare the BP-lowering effects of high-dose (4000 IU/day) vs low-dose (400 IU/day) of cholecalciferol for 6 months in vitamin D deficient individuals. The participants were prehypertensive or hypertensive at baseline and had not been taking antihypertensive drugs. | No significant changes in BP measures was observed in the two groups. Nevertheless, a non-significant (p = 0.71) decrease in 24-h SBP was observed – 0.8 mmHg and –1.6 mmHg in the two groups, respectively. |
| the DAYLIGHT trial. [50]                                             | Multi-center, n = 534                        |                                                                                               |                                                                                                |
| Effect of Vitamin D replacement During Winter Months in Patients With  | Randomized, Double-blind, Placebo-controlled, | To investigate therapeutic effects of 3000 IU/day cholecalciferol for 20 weeks in hypertensive patients. | In the overall group, no significant reductions in 24-h BP, when compared to placebo. A subgroup analysis containing only deficient plasma -25(OH)D (<32 ng/mL) individuals at baseline, showed a significant reduction in 24-h systolic/diastolic BP – 4.1/ –3 mmHg. |
| Hypertension. [51]                                                   | n = 130                                      |                                                                                               |                                                                                                |
| The effect of vitamin D supplementation on arterial stiffness in an   | Randomized, Double-blind, Placebo-controlled, | To compare the effects of 50,000 IU vs. 100,000 IU single-dose intramuscular injection of cholecalciferol in a group of elderly people. | 8 weeks after treatment the group receiving high-dose of cholecalciferol had a significant improvement in arterial stiffness compared to the low-dose group. At the same time, systolic BP seemed to elevate in high-dose group. |
| elderly community-based population. [52]                            | n = 119                                      |                                                                                               |                                                                                                |
| Vitamin D therapy to reduce blood pressure and left ventricular      | Randomized, Double-blind, Placebo-controlled, | To assess effects of high-dose cholecalciferol supplementation (100,000 IU every 2nd month for 6 months) in patients treated with >=3 antihypertensive drugs. | The study showed no improvements in systolic or diastolic BP after 6 months of treatment. |
| hypertrophy in resistant hypertension. [53]                         | n = 68                                       |                                                                                               |                                                                                                |
| Cholecalciferol treatment to reduce blood pressure in older patients  | Randomized, Double-blind, Placebo-controlled, | To explore the effects on BP of high-dose cholecalciferol treatment (100,000 IU every 3rd month for 1 year) in elderly patients with isolated systolic hypertension. | Treatment did not reduce BP or improve other secondary cardiovascular outcomes. |
| with isolated systolic hypertension: the VitDISH randomized controlled | n = 119                                      |                                                                                               |                                                                                                |
| trial. [54]                                                          | ISRCTN92186858                               |                                                                                               |                                                                                                |
| Vitamin D and nifedipine in the treatment of Chinese patients with    | Randomized, Double-blind, Placebo-controlled, | To assess the effects of cholecalciferol (2000 IU/day for 6 months) as ‘add on’ to nifedipine in essential hypertensive patients. | Cholecalciferol as ‘add on’ gave a significant systolic/diastolic BP reduction (-4.2/ -4.2 mmHg). In subgroup analysis of vitamin D insufficient (at baseline) patients, showed – 7.1 / -5.7 mmHg BP reduction (p = 0.001). |
| grades I-II essential hypertension: a randomized placebo-controlled     | n = 126                                      |                                                                                               |                                                                                                |
| trial. [55]                                                          | ChiCTR-ONC-13003840                          |                                                                                               |                                                                                                |
| The effect of vitamin D supplementation on blood pressure in patients  | Randomized, Double-blind, Placebo-controlled, | To assess BP lowering effect of cholecalciferol 50,000 IU/week for 8 weeks in hypertensive, vitamin D deficient patients. | In the vitamin D deficient group (VDC) 92.7% of individuals recovered from insufficiency. Middle arterial pressure (MAP) decreased in average –3.7 mmHg in VDC and increased 0.9 mmHg in place-controls (p < 0.001). |
| with elevated blood pressure and vitamin D deficiency: a randomized,  | n = 42                                       |                                                                                               |                                                                                                |
In summary, animal studies had demonstrated that vitamin D deficiency is associated with high blood pressure by mechanisms revealing a direct effect on the renin-angiotensin-aldosterone axis. An altered vitamin D signalling in different animal models might be involved in cardiovascular diseases such as hypertension, cardiac hypertrophy, and atherosclerosis. Lower serum vitamin D was reported to be associated with higher BP levels in cross-sectional studies [46] and was associated inversely with blood pressure in a large sample representative of the US population [46]. This was supported by basic research. However, there are controversial results of basic research to randomized clinical trials.

A systematic review investigated whether vitamin D supplementation or its analogues may reduce blood pressure [57]. The trial search comprised a period from 1 January 1966, through 31 March 2014. 46 trials with 4541 participants were included in the trial-level meta-analysis [57]. The authors concluded that vitamin D supplementation is not effective as a drug for decreasing blood pressure and is not recommended as an antihypertensive drug [57].

It also has to be taken into account that genetic animal models may not completely reflect vitamin D deficiency of the human organism. Patients with vitamin D deficiency might suffer from chronic illnesses or have unknown cardiovascular risk factors. There might be dietary differences (diet with low vitamin D), differences in outdoor activities or sun-exposure. There is evidence suggesting that vitamin D application has little or no influence on BP, but to answer this point completely new trials are necessary. One example is the ongoing Vitamin D and Omega-3 Hypertension Trial (VITAL Hypertension) (NCT01653678) at Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA. VITAL is an ongoing research study in 25,874 men and women across the U.S. The VITAL Hypertension study is being conducted among participants in VITAL and will examine whether vitamin D or omega-3 fatty acids are related to changes in BP and hypertension.

Another trial which is recruiting is the Vitamin D and Immune Mechanisms of Hypertension in Type 2 Diabetics (VDIM) trial (NCT03348280). This observational study will evaluate whether a particular type of circulating white blood cell, monocytes, from type 2 diabetics with high blood pressure and vitamin D deficiency vs. sufficiency will induce hormones that increase BP.

New international trials can inform about the best vitamin D supplementation dose, and to definitively evaluate the clinical utility of vitamin D therapy. Future studies should consider a design with a large sample size, control of medication, dietary salt and glucose intake, to avoid an activation of the RAAS. Large randomized and long-term trials focusing on patients with severe vitamin D deficiency and hypertension are needed before vitamin D can be recommended for prevention or treatment of hypertension.

The question of whether vitamin D deficiency can cause high BP unfortunately cannot be answered yet.

6. Discussion

The possible beneficial effects of Vitamin D supplementation on BP are the main focus of this review. As mentioned in the previous sections, epidemiological studies find some proof of an inverse correlation between serum vitamin D-status and prevalence of EH. However, the overview of interventional studies in Table 3 does not give a clear picture of vitamin D supplementation in relation to cardiovascular health. It is of interest whether vitamin D therapy in the intervention group (vitamin D deficiency at baseline) is able to raise serum 25(OH)D to the optimal levels (30–80 ng/mL) [58]. Common to the three RCTs is that they all show no effects from vitamin D supplementation in 24-h SBP [52–54]. These three studies share that the intervention groups at time endpoint are still insufficient in serum 25(OH)D levels. Common to Witham et al. trials is the high-dosage of oral administered cholecalciferol (100,000 IU) given at least two months apart [55,54]. This does not seem to restore the 25(OH)D levels, which can possibly explain the lack of effect on BP. In order to obtain positive effects of vitamin D therapy, there is something that suggests the dose interval to be short (e.g., daily or weekly administration).
McGreevy et al. trial participants were given intramuscular injections of 100,000 IU cholecalciferol, which did not restore serum 25(OH)D levels [52]. One possible explanation could be a diminished bioavailability. However, the primary outcome ‘arterial stiffness’ was improved after intervention. This could probably be carried out by an unknown VDR-RXR-protective mechanism in the endothelial wall, independently of renin secretion and the RAAS. Cipriani et al. conclude high-dosage of p.o. administered cholecalciferol to be more efficiently in raising serum 25(OH)D levels, when compared to equivalent intramuscular injections [59]. Hence, future study designs should rather use oral administration than intramuscular injections in the intervention groups.

The DAYLIGHT trial [50] and Styrian trial [49] have the biggest sample size (n = 534 and n = 200) among the RCTs for this review. These trials find no significant changes in measured BP outcomes after a daily administration of vitamin D in the study period.

Larsen et al. found in the overall group no significant BP beneficial effects of vitamin D. Nevertheless, subgroup analysis revealed significant 24-h BP reductions in a subgroup with vitamin D-insufficiency at baseline [51]. One might suggest that there could be a certain threshold in serum 25(OH)D to achieve cardiovascular benefits. Interestingly, Mozaffari-Khosravi et al. observed a remarkably increment in serum 25(OH)D levels and significant MAP reductions at same time [56]. On average, serum levels of 25(OH)D were raised to 51.7 ng/mL in intervention group, which could give support to the idea of a dose-response relation. Hence, study designs with lack of satisfying restoration of serum 25(OH)D levels will fail to improve BP.

Chen et al. investigate the administration of vitamin D as ‘add-on’ to a nifedipine treatment [55]. This combined therapy seems to markedly reduce systolic and diastolic BP—but further studies are needed to elucidate the effects of cholecalciferol and antihypertensive drugs combined.

7. Conclusions and Outlook

Essential hypertension is a condition, in which an imbalance between vasoconstriction and vasodilation occurs. More factors, both epigenetic and environmental, are related to the development of EH. Many epidemiological studies find that vitamin D deficiency can be associated to prevalent hypertension. Furthermore, experimental studies in mice can explain a possible mechanism behind a CVD-protective effect of vitamin D supplementation. Hence, vitamin D injections were shown to inhibit the renin synthesis. This was mediated by the liganded-VDR, which could interact with specific transcription factors to reduce renin transcription. Cholecalciferol can thus be a potentially cost-effective antihypertensive drug.

However, clinical trials in this area show conflicting results—which in part can be attributed to suboptimal study designs. Hence, further studies that efficiently restore serum vitamin D status, are desirable.

Future aspects in this research field include investigating if vitamin D analogues with higher selectivity to VDR could have BP lowering effects. The potential synergistic effect of cholecalciferol and antihypertensive drugs also needs to be further investigated.

Acknowledgments: This review was the bachelor thesis of Christian Legarth.

Author Contributions: Christian Legarth, Marcus Krüger and Daniela Grimm wrote the review; Christian Legarth, Johann Bauer and Markus Wehland searched the trials and checked the references, Marcus Krüger and Christian Legarth made the figures.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation | Description                  |
|--------------|------------------------------|
| 1,25(OH)D | Calcitriol                  |
| 25(OH)D | Calcidiol                   |
| 95%-CI | 95% confidence interval     |
| AC | Adenylate cyclase           |
ACE Angiotensin-converting enzyme
ACEi Angiotensin-converting enzyme inhibitor
ANG Angiotensin
ARB Angiotensin II receptor blocker
AT1/AT2 Angiotensin receptor type 1 or 2
BMI Body mass index
BP Blood pressure
cAMP cyclic adenosine monophosphate
CBP CREB-binding protein
CO Cardiac output
CRE cAMP response element
CREB cAMP-dependent response element binding protein
CVD Cardiovascular disease
CYP Cytochrome P450
DBP Vitamin D binding protein
EH Essential hypertension
HR Heart rate
IU International units
MAP Mean arterial pressure
mRNA messenger ribonucleic acid
NHANES National Health and Nutrition Examination Survey
OR Odds-ratio
PKA Protein kinase A
RAAS Renin-angiotensin-aldosterone system
RCT Randomized controlled trial
RR Relative risk
RXR Retinoid X receptor
SBP Systolic blood pressure
TPR Total periphery resistance
VDR Vitamin D receptor
WHO World Health Organization

References
1. A Global Brief on Hypertension. Available online: http://apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf (accessed on 30 October 2017).
2. Ke, L.; Mason, R.S.; Kariuki, M.; Mpofu, E.; Brock, K.E. Vitamin D status and hypertension: A review. Integr. Blood Press. Control. 2015, 8, 13–35. [PubMed]
3. Mehta, V.; Agarwal, S. Does Vitamin D Deficiency Lead to Hypertension? Cureus 2017, 9, e1038. [CrossRef] [PubMed]
4. Qi, D.; Nie, X.L.; Wu, S.; Cai, J. Vitamin D and hypertension: Prospective study and meta-analysis. PLoS ONE 2017, 12, e0174298. [CrossRef] [PubMed]
5. Geleijnse, J.M. Vitamin D and the Prevention of Hypertension and Cardiovascular Diseases: A Review of the Current Evidence. Am. J. Hypertens. 2011, 24, 253–262. [CrossRef] [PubMed]
6. Vaidya, A.; Forman, J.P. Vitamin D and Hypertension: Current Evidence and Future Directions. Hypertension 2010, 56, 774–779. [CrossRef] [PubMed]
7. Delmi, M.; Rapin, C.H.; Bengoa, J.M.; Delmas, P.D.; Vasey, H.; Bonjour, J.P. Dietary supplementation in elderly patients with fractured neck of the femur. Lancet 1990, 335, 1013–1016. [CrossRef]
8. Shamardl, H.A.; El-Ashmony, S.M.; Kamel, H.F.; Fatani, S.H. Potential Cardiovascular and Renal Protective Effects of Vitamin D and Coenzyme Q10 in L-NAME-Induced Hypertensive Rats. Am. J. Med. Sci. 2017, 354, 190–198. [CrossRef] [PubMed]
9. Mancia, G.; Fagard, R.; Narkiewicz, K.; Redon, J.; Zanchetti, A.; Bohm, M.; Christiaens, T.; Cifkova, R.; De Backer, G.; Dominiczak, A.; et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur. Heart J.* 2013, 34, 2159–2219. [PubMed]
10. Kronborg, C.N.; Hallas, J.; Jacobsen, I.A. Prevalence, awareness, and control of arterial hypertension in Denmark. *J. Am. Soc. Hypertens.* 2009, 3, 19.e2–24.e2. [CrossRef] [PubMed]
11. Whelton, P.K.; Carey, R.M.; Aronow, W.S.; Casey, D.E., Jr.; Collins, K.J.; Dennison Himmelfarb, C.; DePalma, S.M.; Gidding, S.; Jamerson, K.A.; Jones, D.W.; et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension* 2017. [CrossRef]
12. Hill, L.K.; Sollers Iii, J.J.; Thayer, J.F. Resistance reconstructed estimation of total peripheral resistance from computationally derived cardiac output—Biomed 2013. *Biomed. Sci. Instrum.* 2013, 49, 216–223. [PubMed]
13. Laurent, S.; Boutouyrie, P. The structural factor of hypertension: Large and small artery alterations. *Circ. Res.* 2015, 116, 1007–1021. [CrossRef] [PubMed]
14. Lewington, S.; Clarke, R.; Qizilbash, N.; Peto, R.; Collins, R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002, 360, 1903–1913. [CrossRef]
15. Saklayen, M.G.; Deshpande, N.V. Timeline of History of Hypertension Treatment. *Front. Cardiovasc. Med.* 2016, 3, 3. [CrossRef] [PubMed]
16. Hughes, A.D. How do thiazide and thiazide-like diuretics lower blood pressure? *J. Renin Angiotensin Aldoster. Syst.* 2004, 5, 155–160. [CrossRef] [PubMed]
17. Brøsen, K.; Simonsen, U.; Kampmann, J.P.; Thirstrup, S. *Basal Og Klinisk Farmakologi*, 5th ed.; FADL’s Forlag: Copenhagen, Denmark, 2014; ISBN 978-87-7749-683-7.
18. Striessnig, J.; Ortner, N.J.; Pinggera, A. Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets? *Curr. Mol. Pharmacol.* 2015, 8, 110–122. [CrossRef] [PubMed]
19. Mason, R.P.; Giles, T.D.; Sowers, J.R. Evolving mechanisms of action of beta blockers: Focus on nebivolol. *J. Cardiovasc. Pharmacol.* 2009, 54, 123–128. [CrossRef] [PubMed]
20. Van Vark, L.C.; Bertrand, M.; Akkerhuis, K.M.; Brugts, J.J.; Fox, K.; Mourad, J.J.; Boersma, E. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: A meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. *Eur. Heart J.* 2012, 33, 2088–2097. [CrossRef] [PubMed]
21. Abramov, D.; Carson, P.E. The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease. *J. Renin Angiotensin Aldoster. Syst.* 2012, 13, 317–327. [CrossRef] [PubMed]
22. Pool, J.L. Direct renin inhibition: Focus on aliskiren. *J. Manag. Care Pharm.* 2007, 13, 21–33. [CrossRef] [PubMed]
23. Baeke, F.; Takiishi, T.; Korf, H.; Gysemans, C.; Mathieu, C. Vitamin D: Modulator of the immune system. *Curr. Opin. Pharmacol.* 2010, 10, 482–496. [CrossRef] [PubMed]
24. Brumbaugh, P.F.; Haussler, M.R. Nuclear and cytoplasmic binding components for vitamin D metabolites. *Life Sci.* 1975, 16, 353–362. [CrossRef]
25. Wang, Y.; Zhu, J.; DeLuca, H.F. Where is the vitamin D receptor? *Arch. Biochem. Biophys.* 2012, 523, 123–133. [CrossRef] [PubMed]
26. Farrell, C.J.; Herrmann, M. Determination of vitamin D and its metabolites. *Best Pract. Res. Clin. Endocrinol. Metab.* 2013, 27, 675–688. [CrossRef] [PubMed]
27. Razzouke, M.S. Can adverse effects of excessive vitamin D supplementation occur without developing hypervitaminosis D? *J. Steroid Biochem. Mol. Biol.* 2017. [CrossRef] [PubMed]
28. Li, Y.C.; Kong, J.; Wei, M.; Chen, Z.F.; Liu, S.Q.; Cao, L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. *J. Clin. Invest.* 2002, 110, 229–238. [CrossRef] [PubMed]
29. Yuan, W.; Pan, W.; Kong, J.; Zheng, W.; Szeto, F.L.; Wong, K.E.; Cohen, R.; Klopot, A.; Zhang, Z.; Li, Y.C. 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. *J. Biol. Chem.* 2007, 282, 29821–29830. [CrossRef] [PubMed]
30. Kong, J.; Qiao, G.; Zhang, Z.; Liu, S.Q.; Li, Y.C. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. *Kidney Int.* 2008, 74, 1577–1581. [CrossRef] [PubMed]

31. Xiang, W.; Kong, J.; Chen, S.; Cao, L.P.; Qiao, G.; Zheng, W.; Liu, W.; Li, X.; Gardner, D.G.; Li, Y.C. Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems. *Am. J. Physiol. Endocrinol. Metab.* 2005, 288, E125–E132. [CrossRef] [PubMed]

32. Bruckschlegel, G.; Holmer, S.R.; Jandeleit, K.; Grimm, D.; Muders, F.; Kromer, E.P.; Riegger, G.A.; Schunkert, H. Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. *Hypertension* 1995, 25, 250–259. [CrossRef] [PubMed]

33. Grimm, D.; Jabusch, H.C.; Kossmehl, P.; Fredersdorf, S.; Griese, D.P.; Kramer, B.K.; Kromer, E.P. Experimental diabetes and left ventricular hypertrophy: Effects of beta-receptor blockade. *Cardiovasc. Pathol.* 2002, 11, 229–237. [CrossRef] [PubMed]

34. Jurkovicova, D.; Dobesova, Z.; Kunes, J.; Krizanova, O. Different expression of renin-angiotensin system components in hearts of normotensive and hypertensive rats. *Physiol. Res.* 2001, 50, 35–42. [PubMed]

35. Rothermund, L.; Kreutz, R.; Kossmehl, P.; Fredersdorf, S.; Shakibaei, M.; Schulze-Tanzil, G.; Paul, M.; Grimm, D. Early onset of chondroitin sulfate and osteopontin expression in angiotensin II-dependent left ventricular hypertrophy. *Am. J. Hypertens.* 2002, 15, 644–652. [CrossRef] [PubMed]

36. Potter, D.D.; Sobey, C.G.; Tompkins, P.K.; Rossen, J.D.; Heistad, D.D. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. *Circulation* 1998, 98, 800–807. [CrossRef] [PubMed]

37. Szeto, F.L.; Reardon, C.A.; Yoon, D.; Wang, Y.; Wong, K.E.; Chen, Y.; Kong, J.; Liu, S.Q.; Thadhani, R.; Getz, G.S.; et al. Vitamin D receptor signaling inhibits atherosclerosis in mice. *Mol. Endocrinol.* 2012, 26, 1091–1101. [CrossRef] [PubMed]

38. Carey, R.M.; Siragy, H.M. The intrarenal renin-angiotensin system and diabetic nephropathy. *Trends Endocrinol. Metab.* 2003, 14, 274–281. [CrossRef] [PubMed]

39. Wang, J.; Chen, L.; Chen, B.; Meliton, A.; Liu, S.Q.; Shi, Y.; Liu, T.; Deb, D.K.; Solway, J.; Li, Y.C. Chronic Activation of the Renin-Angiotensin System Induces Lung Fibrosis. *Sci. Rep.* 2015, 5, 15561. [CrossRef] [PubMed]

40. Shi, Y.; Liu, T.; Yao, L.; Xing, Y.; Zhao, X.; Fu, J.; Xue, X. Chronic vitamin D deficiency induces lung fibrosis through activation of the renin-angiotensin system. *Sci. Rep.* 2017, 7, 3312. [CrossRef] [PubMed]

41. Kalupahana, N.S.; Moustaid-Moussa, N. The renin-angiotensin system: A link between obesity, inflammation and insulin resistance. *Obes. Rev.* 2012, 13, 136–149. [CrossRef] [PubMed]

42. Shen, L.; Ma, C.; Shuai, B.; Yang, Y. Effects of 1,25-dihydroxyvitamin D3 on the local bone renin-angiotensin system in a murine model of glucocorticoid-induced osteoporosis. *Exp. Ther. Med.* 2017, 13, 3297–3304. [CrossRef] [PubMed]

43. Cheng, Q.; Li, Y.C.; Boucher, B.J.; Leung, P.S. A novel role for vitamin D: Modulation of expression and function of the local renin-angiotensin system in mouse pancreatic islets. *Diabetologia* 2011, 54, 2077–2081. [CrossRef] [PubMed]

44. Chyba, M.M.; Washington, L.R. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–1994. Series 1: Programs and collection procedures. *Vital. Health Stat 1* 1994, 32, 1–407.

45. Martins, D.; Wolf, M.; Pan, D.; Zadshir, A.; Tareen, N.; Thadhani, R.; Felsenfeld, A.; Levine, B.; Mehrotra, R.; Norris, K. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: Data from the Third National Health and Nutrition Examination Survey. *Arch. Intern. Med.* 2007, 167, 1159–1165. [CrossRef] [PubMed]

46. Scragg, R.; Sowers, M.; Bell, C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. *Am. J. Hypertens.* 2007, 20, 713–719. [CrossRef] [PubMed]

47. Kunutsor, S.K.; Apekey, T.A.; Steur, M. Vitamin D and risk of future hypertension: Meta-analysis of 283,537 participants. *Eur. J. Epidemiol.* 2013, 28, 205–221. [CrossRef] [PubMed]

48. Mohr, S.B.; Garland, C.F.; Gorham, E.D.; Garland, F.C. The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. *Diabetologia* 2008, 51, 1391–1398. [CrossRef] [PubMed]
49. Pilz, S.; Gaksch, M.; Kienreich, K.; Grubler, M.; Verheyen, N.; Fahrleitner-Pammer, A.; Treiber, G.; Drechsler, C.; Obermayer-Pietsch, B.; Schwetz, V.; et al. Effects of vitamin D on blood pressure and cardiovascular risk factors: A randomized controlled trial. *Hypertension* 2015, 65, 1195–1201. [CrossRef] [PubMed]

50. Arora, P.; Song, Y.; Dusek, J.; Plotnikoff, G.; Sabatine, M.S.; Cheng, S.; Valcour, A.; Swales, H.; Taylor, B.; Carney, E.; et al. Vitamin D therapy in individuals with prehypertension or hypertension: The DAYLIGHT trial. *Circulation* 2015, 131, 254–262. [CrossRef] [PubMed]

51. Larsen, T.; Mose, F.H.; Bech, J.N.; Hansen, A.B.; Pedersen, E.B. Effect of cholecalciferol supplementation during winter months in patients with hypertension: A randomized, placebo-controlled trial. *Am. J. Hypertens.* 2012, 25, 1215–1222. [CrossRef] [PubMed]

52. McGreevy, C.; Barry, M.; Davenport, C.; Byrne, B.; Donaghy, C.; Collier, G.; Tormey, W.; Smith, D.; Bennett, K.; Williams, D. The effect of vitamin D supplementation on arterial stiffness in an elderly community-based population. *J. Am. Soc. Hypertens.* 2015, 9, 176–183. [CrossRef] [PubMed]

53. Witham, M.D.; Ireland, S.; Houston, J.G.; Gandy, S.J.; Waugh, S.; Macdonald, T.M.; Mackenzie, I.S.; Struthers, A.D. Vitamin D therapy to reduce blood pressure and left ventricular hypertrophy in resistant hypertension: Randomized, controlled trial. *Hypertension* 2014, 63, 706–712. [CrossRef] [PubMed]

54. Witham, M.D.; Price, R.J.; Struthers, A.D.; Donnan, P.T.; Messow, C.M.; Ford, I.; McMurdo, M.E. Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: The VitDISH randomized controlled trial. *JAMA Intern. Med.* 2013, 173, 1672–1679. [CrossRef] [PubMed]

55. Chen, W.R.; Liu, Z.Y.; Shi, Y.; Yin, D.W.; Wang, H.; Sha, Y.; Chen, Y.D. Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II essential hypertension: A randomized placebo-controlled trial. *Atherosclerosis* 2014, 235, 102–109. [CrossRef] [PubMed]

56. Mozaffari-Khosravi, H.; Loloetí, S.; Mirjalili, M.R.; Barzegar, K. The effect of vitamin D supplementation on blood pressure in patients with elevated blood pressure and vitamin D deficiency: A randomized, double-blind, placebo-controlled trial. *Blood Press. Monit.* 2015, 20, 83–91. [CrossRef] [PubMed]

57. Beveridge, L.A.; Struthers, A.D.; Khan, F.; Jorde, R.; Scragg, R.; Macdonald, H.M.; Alvarez, J.A.; Boxer, R.S.; Dalbeni, A.; Gepner, A.D.; et al. Effect of Vitamin D Supplementation on Blood Pressure: A Systematic Review and Meta-analysis Incorporating Individual Patient Data. *JAMA Intern. Med.* 2015, 175, 745–754. [CrossRef] [PubMed]

58. Franczyk, A.; Stolarz-Skrzypek, K.; Wesolowska, A.; Czarnecka, D. Vitamin D and vitamin D receptor activators in treatment of hypertension and cardiovascular disease. *Cardiov. Hematol. Drug Targets* 2014, 14, 34–44. [CrossRef] [PubMed]

59. Cipriani, C.; Romagnoli, E.; Pepe, J.; Russo, S.; Carlucci, L.; Piemonte, S.; Nieddu, L.; McMahon, D.J.; Singh, R.; Minisola, S. Long-term bioavailability after a single oral or intramuscular administration of 600,000 IU of ergocalciferol or cholecalciferol: Implications for treatment and prophylaxis. *J. Clin. Endocrinol. Metab.* 2013, 98, 2709–2715. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).